前列腺癌发生发展的流行病学研究进展

杨进益; 杨明州; 魏伟; 岳文昌

doi:10.13201/j.issn.1001-1420.2017.09.018

前列腺癌发生发展的流行病学研究进展

- 大连医科大学附属大连市友谊医院泌尿外科(辽宁大连, 116001)

详细信息

通讯作者: 杨进益,E-mail:Yangjinyi90@hotmail.com

中图分类号: R737.25

收稿日期: 2017-04-14

Epidemiological study on the occurrence and development of prostate cancer

- Department of Urology, Dalian Friendship Hospitalof Dalian Medical University, Dalian, Liaoning, 116001, China

More Information

Corresponding author: YANG Jinyi, E-mail: Yangjinyi90@hotmail.com

Received Date: 14 April 2017

摘要

摘要: 前列腺癌（prostate cancer，PCa），在欧美是很严重的人类疾病，中国及亚洲PCa发生率增长较快。了解PCa发生发展的流行病学，对于PCa的筛查预防及诊治有重要意义。一般将PCa的危险因素分为不可改变因素与可改变因素。在可改变因素中，对PCa影响较大的有茄红素、硒的摄入，药物中包括5α还原酶抑制剂、他汀类和二甲双胍等，输精管结扎术对PCa的影响也有新观点。本文将新近大样本、有代表性的研究成果进行了综述。
- 前列腺癌 /
- 流行病学
Abstract: Prostate cancer (PCa) is a very serious human disease in Europe and America, and the incidence of PCa is growing rapidly in China and Asia.Understanding the epidemiology of PCa development is of great significance for the prevention and treatment of PCa.Generally, the risk factors of PCa can be divided into non-changing factors and changing factors.Among the factors that could be changed, the influence of lycopene and selenium on PCa was higher.Also, the influence of some medicines was high including 5-alpha reductase inhibitors, statins and metformin and so on.The influence of vasectomy on PCa also has new perspectives.In this paper, a large sample and representative research results are reviewed.
- prostate cancer /
- epidemiology

HTML全文

参考文献(26)

[1]	Nesvadba M, Cmorej P, Mamova A, et al.The incidence, mortality and risk factors of prostate cancer[J].Epidemiol Mikrobiol Imunol, 2016, 65 (4):211-214.
[2]	Hamilton Z, Parsons J K.Prostate Cancer Prevention:Concepts and Clinical Trials[J].Curr Urol Rep, 2016, 17 (4):35.
[3]	Perdana N R, Mochtar C A, Umbas R, et al.The risk factors of prostate cancer and itsprevention:a literature review[J].Acta Med Indones, 2016, 48 (3):228-238.
[4]	Lotan T L, Torres A, Zhang M, et al.Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers[J].Oncotarget, 2017, 8 (14):22772-22782.
[5]	Chen S L, Wang S C, Ho C J, et al.Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 Countries[J].Sci Rep, 2017, 7:40003.
[6]	Xu J, Mo Z, Ye D, et al.Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4[J].Nat Genet, 2012, 44 (11):1231-1235.
[7]	Shi J, Park J H, Duan J, et al.Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data[J].PLoS Genet, 2016, 12 (12):e1006493.
[8]	Magnon C, Hall S J, Lin J, et al.Autonomic nerve development contributes to prostate cancer progression[J].Science, 2013, 341 (6142):1236361.
[9]	Cooperberg M R, Chan J M.Epidemiology of prostate cancer[J].World J Urol, 2017, 35 (6):849.
[10]	Dickerman B A, Ahearn T U, Giovannucci E, et al.Weight change, obesity, and risk of prostate cancer progression among men with clinically localizedprostate cancer[J].Int J Cancer, 2017, 141 (5):933-944.
[11]	Zu K, Mucci L, Rosner B A, et al.Dietary lycopene, angiogenesis, and prostate cancer:aprospective study in the prostate-specific antigen era[J].JNatl Cancer Inst, 2014, 106 (2):djt430.
[12]	Soares N D, Machado C L, Trindade B B, et al.Lycopene Extracts from Different Tomato-Based Food Products Induce Apoptosis in Cultured Human Primary Prostate Cancer Cells and Regulate TP53, Bax and Bcl-2 Transcript Expression[J].Asian Pac J Cancer Prev, 2017, 18 (2):339-345.
[13]	Chan J M, Darke A K, Penney K L, et al.Selenium or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT[J].Cancer Epidemiol Biomarkers Prev, 2016, 25 (7):1050-1058.
[14]	Kenfield S A, Van Blarigan E L, DuPre N, et al.Selenium supplementation and prostate cancer mortality[J].JNatl Cancer Inst, 2014, 107 (1):360.
[15]	Murtola T J, Virkku A, Talala K, et al.Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use[J].JUrol, 2017, pii:S0022-5347 (17) 30290-30292.
[16]	Wadosky K M, Koochekpour S.Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer[J].Int J Biol Sci, 2016, 12 (4):409-426.
[17]	Babcook M A, Joshi A, Montellano J A, et al.Statin Use in Prostate Cancer:An Update[J].Nutr Metab Insights, 2016, 9:43-50.
[18]	Yu O, Eberg M, Benayoun S, et al.Use of statins and the risk of death in patients with prostate cancer[J].JClin Oncol, 2014, 32 (1):5-11.
[19]	Margel D, Urbach D, Lipscombe L L, et al.Association between metformin use and risk of prostate cancer and its grade[J].J Natl Cancer Inst, 2013, 105 (15):1123-1131.
[20]	Chen C B, Eurich D T, Majumdar S R, et al.Metformin and the risk of prostate cancer across racial/ethnic groups:apopulation-based cohort study[J].Prostate Cancer Prostatic Dis, 2017, 20 (1):122-126.
[21]	Margel D, Urbach D R, Lipscombe L L, et al.Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes[J].J Clin Oncol, 2013, 31 (25):3069-3075.
[22]	He X K, Su T T, Si J M, Sun L M, et al.Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus:A Meta-Analysis[J].Medicine (Baltimore), 2016, 95 (7):e2749.
[23]	Morales D R, Morris A D.Metformin in cancer treatment and prevention[J].Annu Rev Med, 2015, 66:17-29.
[24]	Giovannucci E, Ascherio A, Rimm E B, et al.A prospective cohort study of vasectomy and prostate cancer in US men[J].JAMA, 1993, 269 (7):873-877.
[25]	Siddiqui M M, Wilson K M, Epstein M M, et al.Vasectomy and risk of aggressive prostate cancer:a 24-year follow-up study[J].J Clin Oncol, 2014, 32 (27):3033-3038.
[26]	Batruch I, Lecker I, Kagedan D, et al.Proteomic analysis of seminal plasma from normal volunteers and postvasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system[J].JProteome Res, 2011, 10 (3):941-953.